UNIGE document Scientific Article
previous document  unige:19732  next document
add to browser collection
Title

Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial

Authors
Cezard, J-P
Munck, A.
Mouterde, O.
Morali, A.
Lenaerts, C.
Lachaux, A.
Turck, D.
Schmitz, J.
show hidden authors show all authors [1 - 19]
Published in Gastroentérologie clinique et biologique. 2009, vol. 33, no. 1 Pt 1, p. 31-40
Abstract AIM: This study aimed to test the efficacy of mesalazine in maintaining remission in pediatric Crohn's disease (CD) following successful flare-up treatment. METHODS: In this double-blind, randomized, placebo-controlled trial, 122 patients received either mesalazine 50mg/kg per day (n=60) or placebo (n=62) for one year. Treatment allocation was stratified according to flare-up treatment (nutrition or medication alone). Recruitment was carried out over two periods, as the first period's results showed a trend favoring mesalazine. Relapse was defined as a Harvey-Bradshaw score more than or equal to 5. Time to relapse was analyzed using the Cox model. RESULTS: The one-year relapse rate was 57% (n=29) and 63% (n=35) in the mesalazine and placebo groups, respectively. We demonstrated a twofold lower relapse risk (P<0.02) in patients taking mesalazine in the medication stratum (first recruitment period), and a twofold higher risk in patients taking mesalazine in the nutrition stratum (second recruitment period), compared with the other groups. None of the children's characteristics, which differed across the two recruitment periods, accounted for the between-period variation in mesalazine efficacy. One serious adverse event was reported in each treatment group. CONCLUSION: Overall, mesalazine does not appear to be an effective maintenance treatment in pediatric CD.
Keywords Anti-Inflammatory Agents, Non-Steroidal/*therapeutic useChildCrohn Disease/*drug therapyDouble-Blind MethodFemaleHumansMaleMesalamine/*therapeutic useRecurrence/prevention & controlTreatment Outcome
Identifiers
PMID: 19118966
Full text
Structures
Research groups Gastroentérologie et transplantation (pédiatrie) (181)
Plateforme d'oncologie et d'hématologie pédiatrique (907)
Citation
(ISO format)
CEZARD, J-P et al. Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial. In: Gastroentérologie clinique et biologique, 2009, vol. 33, n° 1 Pt 1, p. 31-40. https://archive-ouverte.unige.ch/unige:19732

185 hits

0 download

Update

Deposited on : 2012-04-23

Export document
Format :
Citation style :